HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

lorukafusp alfa

induced immune activation and was associated with reversible clinical toxicities at the MTD of 7.5 mg/m2/d in melanoma patients
Also Known As:
APN-301; APN301; EMD 273063; EMD 273063 antibody, human; EMD-273063; HU 14.18IL2; hu14.18-IL2
Networked: 24 relevant articles (2 outcomes, 10 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1. Sondel, Paul M: 19 articles (01/2021 - 01/2004)
2. Hank, Jacquelyn A: 17 articles (01/2020 - 01/2004)
3. Gillies, Stephen D: 15 articles (01/2019 - 01/2004)
4. Gan, Jacek: 10 articles (10/2019 - 11/2004)
5. Albertini, Mark R: 8 articles (01/2021 - 11/2004)
6. Reisfeld, Ralph A: 8 articles (08/2013 - 01/2004)
7. Rakhmilevich, Alexander L: 7 articles (01/2021 - 01/2004)
8. Kim, KyungMann: 5 articles (01/2020 - 11/2004)
9. Eickhoff, Jens: 5 articles (12/2012 - 11/2004)
10. Gadbaw, Brian: 4 articles (12/2012 - 11/2010)

Related Diseases

1. Neoplasms (Cancer)
2. Neuroblastoma
3. Melanoma (Melanoma, Malignant)
4. Residual Neoplasm
5. Neoplasm Metastasis (Metastasis)

Related Drugs and Biologics

1. Vaccines
2. lorukafusp alfa
3. Interleukin-2 (IL2)
4. Monoclonal Antibodies
5. Fenretinide
6. Isotretinoin (Accutane)
7. Tumor Biomarkers (Tumor Markers)
8. Retinoids
9. Interleukin-2 Receptors (IL 2 Receptor)
10. KIR Receptors

Related Therapies and Procedures

1. Therapeutics
2. Intravenous Infusions
3. Immunotherapy
4. Radiotherapy
5. Injections